Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Receivables (2016 - 2025)

Altimmune (ALT) has disclosed Change in Receivables for 16 consecutive years, with $374000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 222.41% to $374000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $675000.0 through Dec 2025, up 219.05% year-over-year, with the annual reading at $675000.0 for FY2025, 219.05% up from the prior year.
  • Change in Receivables for Q4 2025 was $374000.0 at Altimmune, down from $524000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $741000.0 in Q3 2023, with the low at -$3.1 million in Q3 2021.
  • Average Change in Receivables over 5 years is -$169550.0, with a median of $3500.0 recorded in 2022.
  • The sharpest move saw Change in Receivables tumbled 4000.0% in 2023, then skyrocketed 13000.0% in 2025.
  • Over 5 years, Change in Receivables stood at -$1.1 million in 2021, then soared by 59.83% to -$460000.0 in 2022, then surged by 150.87% to $234000.0 in 2023, then plummeted by 50.43% to $116000.0 in 2024, then surged by 222.41% to $374000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $374000.0, $524000.0, and -$186000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.